Phase I/II Trial of Olaparib and Radium-223 in Advanced Prostate Cancer
This trial is investigating the safety and efficacy of olaparib in combination with radium-223 for patients with metastatic castration-resistant prostate cancer.
Asset / Drug
Drug and asset intelligence for Olaparib with 10 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
Combination Therapy
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.